著者名,論文名,雑誌名,ISSN,出版者名,出版日付,巻,号,ページ,URL,URL(DOI)
Shukui Qin and Stephen L Chan and Shanzhi Gu and Yuxian Bai and Zhenggang Ren and Xiaoyan Lin and Zhendong Chen and Weidong Jia and Yongdong Jin and Yabing Guo and Xiaohua Hu and Zhiqiang Meng and Jun Liang and Ying Cheng and Jianping Xiong and Hong Ren and Fang Yang and Wei Li and Yajin Chen and Yong Zeng and Alexander Sultanbaev and Monika Pazgan-Simon and Margaryta Pisetska and Davide Melisi and Dmitriy Ponomarenko and Yurii Osypchuk and Ivan Sinielnikov and Tsai-Sheng Yang and Xiao Liang and Chunxia Chen and Linna Wang and Ann-Lii Cheng and Ahmed Kaseb and Arndt Vogel and Mingxiang Zhang and Li Xu and Xianglin Yuan and Da Li and Jierer Ying and Jingdong Zhang and Tao Zhang and Kangsheng Gu and Yifu He and Ping Hao and Da Jiang and Shu Zhang and Baocai Xing and Baihong Zhang and Dong Wang and Xiaofeng Zhai and Houjie Liang and Bozena Cybulska-Stopa and Mikhail Dvorkin and Daniil Stroyakovskiy and Marina Nechaeva and Chia-Jui Yen and Wei-Wen Su and Yen-Hao Chen and Igor Bondarenko and Lin Yang and Weijia Fang and Carlos Gomez-Martin and Min-Hee Ryu and Han-Sang Kim and Jee-Hyun Kim and Oleg Zarubenkov and Rashida Orlova and Elena Poddubskaya and Natalia Fadeeva and Yulia Makarova and Yee Chao and Chao-Hung Hung and Maryna Neffa and Oleksandr Vynnychenko and Adam Burgoyne and Chunyi Hao and Raphael U Mohr and Roberto Diaz-Beveridge and Jaime Feliu-Batlle and Antonio Cubillo-Gracian and Ann-Shing Lee and Bruno Daniele and Lorenzo Antonuzzo and Angelo Sangiovanni and Antonio Gasbarrini and Mario Scartozzi and Mi Sun Ahn and Sung-Yong Oh and Sergey Orlov and Hakan Harputluoglu and Berna Oksuzoglu and Chiun Hsu and Kun-Ming Rau and Oleksandr Krechkovskyi and Vladimir Yareshko and Henry Xiong and Fa-Chyi Lee and Yixing Jiang and Afshin Gabayan and Mary Crow and Christophe Van Steenkiste and Gontran Verset,"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study",The Lancet,0140-6736,Elsevier BV,2023-09,402,10408,1133-1146,https://cir.nii.ac.jp/crid/1360580931195437696,https://doi.org/10.1016/s0140-6736(23)00961-3